Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cinacalcet. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR known ✓ | P41180 | 5/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 3/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 3/20 | 1.00 |
| ▸ | DRD3 | P35462 | 3/20 | 1.00 |
| ▸ | HTR2C | P28335 | 3/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 1/20 | 1.00 |
| ▸ | GLRA1 | P23415 | 1/20 | 1.00 |
| ▸ | AVPR2 | P30518 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | MC3R | P41968 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cinacalcet SCHEMBL29360301 | 1.00 | CASR (1.00) | CASRADRA2CSLC6A4DRD3HTR2C | |
| Cinacalcet SCHEMBL71876 | 1.00 | CASR (1.00) | CASRADRA2CSLC6A4DRD3HTR2C | |
| Cinacalcet SCHEMBL29373418 | 1.00 | CASR (1.00) | CASRADRA2CSLC6A4DRD3HTR2C | |
| Cinacalcet SCHEMBL3227084 | 1.00 | CASR (1.00) | CASRADRA2CSLC6A4DRD3HTR2C | |
| Cinacalcet SCHEMBL30371982 | 1.00 | CASR (1.00) | CASRADRA2CSLC6A4DRD3HTR2C | |
| Cinacalcet SCHEMBL1179140 | 0.99 | CASR (1.00) | CASRADRA2CSLC6A4DRD3HTR2C | |
| Cinacalcet SCHEMBL195640 | 0.99 | CASR (1.00) | CASRADRA2CSLC6A4DRD3HTR2C | |
| Cinacalcet SCHEMBL29364854 | 0.99 | CASR (1.00) | CASRADRA2CSLC6A4DRD3HTR2C | |
| Cinacalcet SCHEMBL30482673 | 0.99 | CASR (1.00) | CASRADRA2CSLC6A4DRD3HTR2C | |
| Cinacalcet SCHEMBL29363135 | 0.99 | CASR (1.00) | CASRADRA2CSLC6A4DRD3HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102414-A1 | USE OF DERIVATIVES CONTAINING C-O-P BONDS IN PATIENTS WITH KIDNEY FAILURE | SANIFIT THERAPEUTICS S A (ES) | 2026-04-16 | — | — | US | claimed |
| US-20250295676-A1 | INOSITOL PHOSPHATE COMPOUNDS FOR USE IN TREATING, INHIBITING THE PROGRESSION, OR PREVENTING CARDIOVASCULAR CALCIFICATION | VIFOR (INTERNATIONAL) LTD. (CH) | 2025-09-25 | — | — | US | claimed |
| US-20230147129-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES | UNIVERSITAT AUTÒNOMA DE BARCELONA (ES) | 2023-05-11 | — | — | US | claimed |
| US-20220249521-A1 | USE OF DERIVATIVES CONTAINING C-O-P BONDS IN PATIENTS WITH KIDNEY FAILURE | Sanifit Therapeutics S.A. (ES) | 2022-08-11 | — | — | US | claimed |
| EP-2642980-B1 | PEDIATRIC FORMULATION | AMGEN INC (US) | 2020-04-08 | — | — | EP | claimed |
| US-10010559-B2 | Use of derivatives containing C-O-P bonds in patients with kidney failure | LABORATORIOS SANIFIT, S.L. (ES) | 2018-07-03 | — | — | US | claimed |
| CN-106543010-A | A kind of method of synthetic hydrochloric acid cinacalcet | 上海清松制药有限公司 | 2017-03-29 | — | — | CN | claimed |
| US-20170020903-A1 | USE OF DERIVATIVES CONTAINING C-O-P BONDS IN PATIENTS WITH KIDNEY FAILURE | VIFOR (INTERNATIONAL) LTD. (CH) | 2017-01-26 | — | — | US | claimed |
| WO-2010010359-A2 | A PROCESS FOR THE PREPARATION OF CINACALCET AND ITS SALTS | CILPA LIMITED (IN) | 2010-01-28 | — | — | WO | claimed |
| US-20250295676-A1 | INOSITOL PHOSPHATE COMPOUNDS FOR USE IN TREATING, INHIBITING THE PROGRESSION, OR PREVENTING CARDIOVASCULAR CALCIFICATION | VIFOR (INTERNATIONAL) LTD. (CH) | 2025-09-25 | — | — | US | disclosed |
| US-12129268-B2 | Chiral N-substituted allylic amine compounds | UNIVERSITY OF LOUISIANA AT LAFAYETTE (US) | 2024-10-29 | — | — | US | disclosed |
| US-20230147129-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES | UNIVERSITAT AUTÒNOMA DE BARCELONA (ES) | 2023-05-11 | — | — | US | disclosed |
| US-20230147129-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES | UNIVERSITAT AUTÒNOMA DE BARCELONA (ES) | 2023-05-11 | — | — | US | disclosed |
| CN-111574323-B | Preparation method of R-1- (naphthalene-1-yl) ethanol | 中山奕安泰医药科技有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-20070260091-A1 | Process for the preparation of cinacalcet base | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-11-08 | — | — | US | disclosed |
| US-20070260091-A1 | Process for the preparation of cinacalcet base | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-11-08 | — | — | US | disclosed |
| US-7250533-B2 | Process for preparing Cinacalcet hydrochloride | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2007-07-31 | — | — | US | disclosed |
| US-7250533-B2 | Process for preparing Cinacalcet hydrochloride | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2007-07-31 | — | — | US | disclosed |
| US-20070043243-A1 | Process for preparing Cinacalcet hydrochloride | TEVA PHARMACEUTICALS USA, INC. | 2007-02-22 | — | — | US | disclosed |
| US-20070043243-A1 | Process for preparing Cinacalcet hydrochloride | TEVA PHARMACEUTICALS USA, INC. | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170020903-A1 | USE OF DERIVATIVES CONTAINING C-O-P BONDS IN PATIENTS WITH KIDNEY FAILURE | ATP6V1B1, PROC, GC | CASR 49/4885ADRA2C 1657/4885SLC6A4 1172/4885 |
| US-20250295676-A1 | INOSITOL PHOSPHATE COMPOUNDS FOR USE IN TREATING, INHIBITING THE PROGRESSION, OR PREVENTING CARDIOVASCULAR CALCIFICATION | PPIP5K2, INPP5B, IP6K3 | CASR 46/4885ADRA2C 3117/4885SLC6A4 2731/4885 |
| US-12129268-B2 | Chiral N-substituted allylic amine compounds | HNMT, NNMT, TPMT | CASR 1821/4885ADRA2C 155/4885SLC6A4 23/4885 |
| US-20220249521-A1 | USE OF DERIVATIVES CONTAINING C-O-P BONDS IN PATIENTS WITH KIDNEY FAILURE | ATP6V1B1, PROC, GC | CASR 43/4885ADRA2C 1680/4885SLC6A4 1208/4885 |
| US-20070260091-A1 | Process for the preparation of cinacalcet base | KRAS, CA9, SI | CASR 339/4885ADRA2C 1918/4885SLC6A4 798/4885 |
| US-20230147129-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES | SNCA, PARK7, PRNP | CASR 4772/4885ADRA2C 441/4885SLC6A4 802/4885 |
| US-20260102414-A1 | USE OF DERIVATIVES CONTAINING C-O-P BONDS IN PATIENTS WITH KIDNEY FAILURE | ATP6V1B1, IP6K3, IP6K1 | CASR 28/4885ADRA2C 2090/4885SLC6A4 504/4885 |
| US-20070043243-A1 | Process for preparing Cinacalcet hydrochloride | SI, PRCP, CA9 | CASR 284/4885ADRA2C 1384/4885SLC6A4 1294/4885 |
| US-10010559-B2 | Use of derivatives containing C-O-P bonds in patients with kidney failure | ATP6V1B1, PROC, GC | CASR 43/4885ADRA2C 1680/4885SLC6A4 1208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.